Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Avitar's (OTC:AVTI) Diagnostic Test Business Stopped Filing With the SEC Around 2010

Avitar, Inc (OTC:AVTI) was once a functioning medical-diagnostics manufacturer with a real product line, but the ticker now trades at essentially the lowest price a quote can register, a small fraction of a cent, with aMarket Valueof only a few hundred dollars. The company's …

Nitish Kishor | 10 September 2026

Avitar's (OTC:AVTI) Diagnostic Test Business Stopped Filing With the SEC Around 2010

Avitar, Inc (OTC:AVTI) was once a functioning medical-diagnostics manufacturer with a real product line, but the ticker now trades at essentially the lowest price a quote can register, a small fraction of a cent, with aMarket Valueof only a few hundred dollars. The company's …

Nitish Kishor | 10 September 2026

Aardvark Therapeutics, Inc (NASDAQ:AARD) Slides: What Investors Need to Know

● The stock's roughly 7.7% slide in the latest session does not map to a single, separately verified same-day catalyst.

Nitish Kishor | 10 September 2026

This OTC:ABTI Cannabinoid Stock Kept Filing With the SEC Long After Peers Went Dark

Among the sub-penny cannabinoid names still listed over the counter, Alterola Biotech, Inc. (OTC:ABTI) stands out for a simple reason: unlike many peers that went silent years ago, it kept filing with the U.S. Securities and Exchange Commission well into the mid-2020s. That relative …

Nitish Kishor | 10 September 2026

Bio-Path Holdings (OTC:BPTH) Stock Explodes Higher: Why It Is Suddenly on Traders' Radar

● A triple-digit percentage jump in a stock trading at a few cents is almost always a story about liquidity, not fundamentals, and Bio-Path Holdings.

Nitish Kishor | 10 September 2026

BioRestorative Therapies (NASDAQ: BRTX) Turns Lower: Why Investors Are Reassessing

BioRestorative Therapies, Inc. (NASDAQ: BRTX) has been building a clinical case for stem-cell treatment of chronic back pain, yet its shares slipped in early-September trading even after reporting encouraging trial data earlier in 2026. The pullback in the BRTX ticker flagged by market feeds …

Nitish Kishor | 10 September 2026

Procter & Gamble Director Receives RSU Grant

Director Christine M. McCarthy filed a Form 4 with the SEC on September 10, 2026, reporting the acquisition of 258 shares of Procter & Gamble common stock in the form of Restricted Stock Units on September 8, 2026.

Shwetambri Chauhan | 10 September 2026

CONMED Director Kim Kelderman Reports RSU Grant

A Form 4 filed on September 10, 2026 discloses that Kim Kelderman, a director of CONMED Corp (NASDAQ:CNMD), received a grant of 500 restricted stock units on September 8, 2026 under the company's 2025 Long-Term Incentive Plan.

Aakashdeep | 10 September 2026

BioStem Technologies (NASDAQ:BSEM) Stock: A Nasdaq Uplisting Meets New Hospital Contracts

BioStem Technologies, Inc (NASDAQ:BSEM) has had an eventful 2026, capped by a move that many small companies aspire to but few complete: a graduation from over-the-counter trading to the Nasdaq Capital Market. With the shares recently pushing higher and the company stacking up distribution …

Nitish Kishor | 10 September 2026

HeartBeam (NASDAQ:BEAT) Stock: Shares Slide as the Company Pivots to Licensing

HeartBeam, Inc. (NASDAQ:BEAT) slipped roughly 6% in a recent session, a reminder of how volatile small-cap medical-technology stocks can be. The Nasdaq-listed company, ticker BEAT, is developing a credit-card-sized device meant to capture 12-lead-equivalent ECG data outside the clinic, potentially detecting heart attacks at …

Nitish Kishor | 10 September 2026
Support

Hi! How can we help you today?

Loading…